First Wave BioPharma Inc(AzurRx BioPharma): Analysts are Bullish with massive upside, $5.00 target

STA Research
by: STA Research

Based on the First Wave BioPharma Inc stock forecasts from 2 analysts, the average analyst target price for First Wave BioPharma Inc is USD 5.50 over the next 12 months. First Wave BioPharma Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of First Wave BioPharma Inc is Neutral, which is based on 0 positive signals and 0 negative signals. At the last closing, First Wave BioPharma Inc’s stock price was USD 0.17First Wave BioPharma Inc’s stock price has changed by -20.70% over the past week, -43.17% over the past month and 0% over the last year.

AzurRx BioPharma  purchased First Wave Bio, in both a stock and cash deal offer which was valued at $229 million. AzurRx has since changed it’s name to operate under the label First Wave.

What we like:

There is no fundamental attribute that we can detect on the stock that would warrant a positive outlook.

What we don’t like:

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Disclaimer

Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.

Leave a Reply

Your email address will not be published.